Oxurion Announces Capital Increase Following Convertible Bond Conversion

Atlas Special Opportunities, LLC has converted six convertible bonds, resulting in a EUR 150,000 capital increase for Oxurion. This conversion is part of Atlas's EUR 20 million commitment to support Oxurion’s development of therapeutics for elderly vision care.

As of March 21, 2025, Oxurion issued 996,319 new ordinary shares, raising the total to 4,634,663 shares with voting rights, compared to the previous 3,638,344 shares. This change updates the denominator used for shareholding percentages calculation.

Oxurion's share capital now stands at EUR 85,556,161.32. Additionally, there are outstanding rights to subscribe to new securities based on previous agreements, which are currently out-of-the-money.

These financial steps underscore Oxurion's strategic focus on advanced ophthalmic therapies, aiming to seize potential market opportunities valued between USD 3-6 billion.